Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Time：2018-09-21Source : AmoyDx
◎ AmoyDx Essential NGS Panel: Focused on 10 oncogenes approved by FDA for targeted drugs.
◎ Super-ARMS EGFR: Significant improvement on qPCR platform of liquid biopsy EGFR testing.
AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market
AmoyDx Collaborates with AstraZeneca to Co-develop HRD Companion Diagnostics for Ovarian Cancer
AmoyDx at WCLC 2020 wrap-up
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market
AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide